AstraZeneca announced positive high-level data from the HIMALAYA Phase III trial of a single, high priming dose of tremelimumab plus Imfinzi (durvalumab) in patients with unresectable hepatocellular carcinoma (HCC), or liver cancer, who had not had previous systemic therapy and were not eligible for localized treatment.
In October 2020, the government recommended against kids going trick-or-treating for Halloween out of fear of Covid-19 spread. For Halloween 2021, kids have been given the green light to knock on doors.
AstraZeneca’s antibody cocktail against Covid-19, which has proven to work as a preventative shot in the non-infected, was also shown to save lives and prevent severe disease when given as treatment within a week of first symptoms.
Four months after forging a collaboration to develop an experimental atopic dermatitis treatment, Amgen and Japan’s Kyowa Kirin are beginning to see the fruits of that deal with positive Phase II data for AMG 451/KHK4083, a potential first-in-class anti-OX40 monoclonal antibody.
Monoclonal antibodies are playing a key therapeutic role in the treatment of some Covid-19 patients, but new research suggests that nanobodies derived from llamas could provide an alternative to monoclonal antibodies through a more effective delivery method—inhalation.
Early data from a Phase III study of Brii Biosciences’ monoclonal antibody combination therapy for Covid-19 is showing significant promise.
Trial data from AstraZeneca on Aug. 20 raised the prospect of a new treatment to prevent Covid-19 beyond vaccines, giving hope in particular for people who respond poorly to immunization shots.
The UK drug regulator approved an antibody cocktail developed by Regeneron and Roche to prevent and treat Covid-19, as the nation battles rising hospitalizations due to the more infectious Delta variant.
Junshi Biosciences announced that the Phase III clinical trial the Chinese pharmaceutical company is conducting alongside California-based Coherus BioSciences on a potential non-small cell lung cancer (NSCLC) drug is showing positive preliminary results.
An experimental monoclonal antibody developed at the U.S. National Institutes of Health (NIH) prevented malaria for up to nine months in volunteers exposed to the disease-causing parasite in a small trial, researchers reported on Aug. 11 in the New England Journal of Medicine.